Open an account

DarioHealth

DRIO · NASDAQ

$4.08−$0.41 (−9.13%)TodayMarket closed ·
Prev close $4.49

About DRIO

DarioHealth Corp. is a digital health company which offers a user-centric and multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company is headquartered in New York City, New York and currently employs 160 full-time employees. The company went IPO on 2013-03-08. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management.

Employees
160
Headquarters
New York City, New York
Listed
Mar 8, 2013
Sector
Health Care
Industry
Health Care Technology
Website
shop.mydario.com

DRIO key statistics

Market cap
39.98M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
20.12K
Volume
132.92K
Open price
$4.49
High today
$4.62
Low today
$3.85
52 Week high
$16.50
52 Week low
$4.49

DarioHealth (DRIO) at a glance

As of Oct 20, 2026, DarioHealth (DRIO) shares are priced at $4.08, giving the company a market cap of 39.98M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.85 and $4.62. The current price is 6.0% above the day's low and 11.7% below its high.

Volume so far is 132.92K shares, above the average of 20.12K shares a day.

Over the past year DarioHealth has ranged from $4.49 to $16.50, and now sits -3% of the way up that range.

DarioHealth met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.85 per share against an estimate of -$1.24.

The average analyst price target is $13.87, 240.0% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 3 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 7 analystsAvg $13.87
Low
$8.08
Now
$4.08
High
$29.40

DRIO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 52.7% on average.

  1. Q3 FY24: reported -$5.00 per share against an estimate of -$5.58
  2. Q4 FY24: reported -$1.80 per share against an estimate of -$6.80
  3. Q1 FY25: reported -$2.80 per share against an estimate of -$2.38
  4. Q2 FY25: reported -$3.60 per share against an estimate of -$4.76
  5. Q3 FY25: reported $2.96 per share against an estimate of -$5.00
  6. Q4 FY25: reported -$3.43 per share against an estimate of -$3.31
  7. Q1 FY26: reported -$1.25 per share against an estimate of -$1.51
  8. Q2 FY26: reported -$0.85 per share against an estimate of -$1.24

DRIO news

  • Press releasePRNewswire

    DarioHealth Announces Independent Aon Analysis that Supports Estimated 2.5%-7.2% In-Year Reduction in Total Healthcare Costs

  • Press releasePRNewswire

    Dario Wins Contract with One of New Jersey's Largest Health Plans Representing 1.5 Million Covered Lives

  • Press releasePRNewswire

    DarioHealth Reports Second Quarter 2026 Financial Results

  • Press releasePRNewswire

    Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand

  • Press releasePRNewswire

    DarioHealth to Report Second Quarter 2026 Results on Tuesday, August 11, 2026

  • Press releasePRNewswire

    Dario Launches Integrated GLP-1 Program, Combining Its Digital Chronic Care Platform with Provider-Backed Clinical Care in a Single End-to-End Experience

  • Press releasePRNewswire

    Dario Announces Pricing of a $23.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

  • Press releasePRNewswire

    Fortune 50 Employer Awards Dario Contract to Deliver AI-Powered Cardiometabolic Care Platform

Similar companies

Companies in the same industry as DarioHealth

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.